906670-24-4

Basic information

• Product Name: L-Alanine, N-[chloro(1-naphthalenyloxy)phosphinyl]-, phenylmethyl ester
• CAS NO: 906670-24-4
• Molecular Formula: C20H19ClNO4P
• Molecular Weight: 403.802
• Mol File: 906670-24-4.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: L-Alanine, N-[chloro(1-naphthalenyloxy)phosphinyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Alanine, N-[chloro(1-naphthalenyloxy)phosphinyl]-, phenylmethyl ester(906670-24-4)
• EPA Substance Registry System: L-Alanine, N-[chloro(1-naphthalenyloxy)phosphinyl]-, phenylmethyl ester(906670-24-4)

Safety Data

• Hazardous Substances Data: 906670-24-4(Hazardous Substances Data)

Upstream product

• 31651-76-0 1-naphthyl dichlorophosphate 
• 17831-01-5 H-Ala-OBzl 
• 90-15-3 α-naphthol 
• 42854-62-6 L-alanine benzyl ester p-toluenesulfonate 

Downstream Products

• 1029347-51-0 2',3'-O,O-cyclopentylidene-β-2'-methyl-adenosine 5'-O-[α-naphthyl(benzoxy-L-alaninyl)] phosphate 
• 1029347-55-4 2',3'-O,O-isopropylidene-β-2'-methyl-guanosine 5'-O-[α-naphthyl(benzoxy-L-alaninyl)] phosphate 
• 1059581-15-5 N⁽²⁾-DMFacyclovir-[1-naphthyl(benzoxy-L-alaninyl)]phosphate 
• 1170666-28-0 C₃₅H₃₅N₈O₉P 
• 1218784-99-6 C₃₃H₃₇N₈O₈P 
• 1332837-31-6 5'-[1-naphthyloxy-((S)-(1-benzyloxycarbonylethyl)amino)phosphoryl]-5-fluoro-2'-deoxyuridine 
• 1332837-32-7 C₂₉H₂₉FN₃O₉P 
• 1285658-65-2 C₃₀H₃₁N₆O₉P 

Relevant articles and documents

Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs

Unmasked phohate groups of phosphotyrosine-containing molecules carry two negative charges at physiological pH, which compromise their (passive) cellular uptake. Also, these phosphate groups are often cleaved off by phosphatases. Together, these ultimatel

MONOSACCHARIDE PHOSPHORAMIDATE PRODRUGS

The present disclosure provides monosaccharide phosphoramidate prodrugs of monosaccharide monophosphates. The present disclosure further provides methods of treating diseases of conditions such as congenital disorders of glycosylation comprising administering the monosaccharide phosphoramidate prodrugs of the present disclosure to a patient in need thereof.

FLOXURIDINE SYNTHESIS

The present invention relates to a process for the preparation of floxuridine, said process comprising reacting a compound of Formula la with a compound of Formula lla in the presence of an acid Al to provide a compound of Formula Ilia in substantially diastereomerically pure form. Floxuridine may be useful as an anti-cancer drug. Floxuridine may also be useful in the preparation of other anti-cancer drugs, e.g. NUC-3373.